NCT04998201Phase 2Completed

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Study sponsor: Arrowhead Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-02-10Actual
Enrollment · participants353Actual
Source updated2026-04-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting TG.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview